These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26040853)

  • 1. Targetable mutations found in metastatic prostate cancer.
    Balakrishnan VS
    Lancet Oncol; 2015 Jul; 16(7):e316. PubMed ID: 26040853
    [No Abstract]   [Full Text] [Related]  

  • 2. Is there an optimal treatment sequencing strategy for metastatic castration-resistant prostate cancer?
    Aragon-Ching JB
    Future Oncol; 2013 May; 9(5):619-22. PubMed ID: 23647288
    [No Abstract]   [Full Text] [Related]  

  • 3. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.
    Taplin ME; Rajeshkumar B; Halabi S; Werner CP; Woda BA; Picus J; Stadler W; Hayes DF; Kantoff PW; Vogelzang NJ; Small EJ;
    J Clin Oncol; 2003 Jul; 21(14):2673-8. PubMed ID: 12860943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continued targeting of androgen receptor signalling: a rational and efficacious therapeutic strategy in metastatic castration-resistant prostate cancer.
    Bianchini D; de Bono JS
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S189-94. PubMed ID: 21943974
    [No Abstract]   [Full Text] [Related]  

  • 5. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.
    Taplin ME; Bubley GJ; Shuster TD; Frantz ME; Spooner AE; Ogata GK; Keer HN; Balk SP
    N Engl J Med; 1995 May; 332(21):1393-8. PubMed ID: 7723794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutated androgen receptors of prostate-cancer cells.
    Figg WD; Middleman M; Sartor O
    N Engl J Med; 1995 Oct; 333(15):1010-1. PubMed ID: 7666906
    [No Abstract]   [Full Text] [Related]  

  • 7. [Alteration of androgen receptor cofactor in prostate cancer].
    Tozawa K; Hashimoto Y; Yasui T
    Nihon Rinsho; 2016 May; 74 Suppl 3():93-8. PubMed ID: 27344710
    [No Abstract]   [Full Text] [Related]  

  • 8. Intermittent androgen deprivation therapy: conventional wisdom versus evidence.
    Tombal B
    Eur Urol; 2009 Jun; 55(6):1278-80. PubMed ID: 19303201
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of locally spread prostate cancer].
    Tammela T
    Duodecim; 2005; 121(16):1779-82. PubMed ID: 16268225
    [No Abstract]   [Full Text] [Related]  

  • 10. [Mutation of androgen receptor].
    Sakamoto S; Goto Y; Ichikawa T
    Nihon Rinsho; 2016 May; 74 Suppl 3():87-92. PubMed ID: 27344709
    [No Abstract]   [Full Text] [Related]  

  • 11. [Prostate cancer and apoptosis].
    Mayora A; Arvelo F
    Invest Clin; 2011 Dec; 52(4):376-96. PubMed ID: 22523847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
    Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
    Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; George DJ
    Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):108-16. PubMed ID: 20066005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor mutations in prostate cancer.
    Marcelli M; Ittmann M; Mariani S; Sutherland R; Nigam R; Murthy L; Zhao Y; DiConcini D; Puxeddu E; Esen A; Eastham J; Weigel NL; Lamb DJ
    Cancer Res; 2000 Feb; 60(4):944-9. PubMed ID: 10706109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biology of castration-recurrent prostate cancer.
    Azzouni F; Mohler J
    Urol Clin North Am; 2012 Nov; 39(4):435-52. PubMed ID: 23084522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor mutations are associated with Gleason score in localized prostate cancer.
    Sanchez D; Rosell D; Honorato B; Lopez J; Arocena J; Sanz G
    BJU Int; 2006 Dec; 98(6):1320-5. PubMed ID: 17034507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of prostate cancer progression to androgen independence.
    McPhaul MJ
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):373-88. PubMed ID: 18471793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms leading to the development of hormone-resistant prostate cancer.
    Kasper S; Cookson MS
    Urol Clin North Am; 2006 May; 33(2):201-10, vii. PubMed ID: 16631458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor signaling in prostate cancer.
    Culig Z; Santer FR
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):413-27. PubMed ID: 24384911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The fringe benefits of cloning cancer.
    Kyprianou N
    Sci Transl Med; 2014 Sep; 6(254):254fs36. PubMed ID: 25232174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.